Technology area: Biotechnology & Pharmaceuticals
27 pending office actions • 16 clients • 26 examiners • 18 art units • 0 of 27 (0%) have an AI response strategy ready
LICATA & TYRRELL P.C. has 2,256 career applications in Biotechnology & Pharmaceuticals and 29 pending office actions. The figures show a developed prosecution history and an active current docket.
The resolved allowance rate is 68.02%, and the average is 4.3 office actions per allowance. The allowance measure describes resolved outcomes, while the action average indicates substantial examination activity among matters that reached allowance.
Practitioners can use the pending count for immediate docket planning and the historical measures to assess the prosecution effort reflected in the record. Application-level review is needed to determine whether current matters follow the same patterns.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (11%) |
| §103 only | 6 (22%) |
| §112 only | 4 (15%) |
| Double-patenting + other | 6 (22%) |
| Multi-statute (no §101) | 7 (26%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 2 | 53.8% | +64.6% |
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| HWU, JUNE | 1 | 91.3% | -2.0% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
| TINSLEY, BRENDAN THOMAS | 1 | 60.4% | +74.3% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| MOLOYE, TITILAYO | 1 | 62.3% | +48.3% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
| 18268032 | BURKHOLDERIA VACCINES AND THERAPEUTICS | MORGAN, BAILEY MICHELLE | 14d |
| 17919622 | SYSTEM AND METHOD FOR MICRODIALYSIS FOR IN-VITRO RELEASE TESTING OF DOSAGE FORMS | HERBERT, MADISON TAYLOR | 34d |
| 19065181 | STEM CELL-SPECIFIC PROMOTER FROM SACCHARUM AND METHODS FOR INCREASING FATTY ACID AND/OR OIL ACCUMULATION | HWU, JUNE | — |
| 18961853 | Single Cell Encapsulation in Compartmentalized Hydrogel Coatings | THUESON, HANNA MARIE | — |
| 18805952 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | FIEBIG, RUSSELL G | — |
| 18723927 | NONHUMAN STEM CELLS AND THEIR USE FOR PRODUCTION OF CULTURED MEAT | MOLOYE, TITILAYO | — |
| 18427042 | METHOD OF USING PACAP AND VIP PEPTIDES FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS | LU, CHENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
| 19558906 | METHODS AND COMPOSITIONS FOR REDUCING MUSCLE LOSS AND/OR INHIBITING SARCOPENIA ASSOCIATED WITH WEIGHT LOSS | BOECKELMAN, JACOB A | — |
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | PAK, MICHAEL D | — |
| 18961853 | Single Cell Encapsulation in Compartmentalized Hydrogel Coatings | THUESON, HANNA MARIE | — |
| 18848589 | Adenoviral Mediated Targeting of Activated Immune Cells | TINSLEY, BRENDAN THOMAS | — |
| 18805952 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | FIEBIG, RUSSELL G | — |
| 18723927 | NONHUMAN STEM CELLS AND THEIR USE FOR PRODUCTION OF CULTURED MEAT | MOLOYE, TITILAYO | — |
| 18706257 | TRANSPOSABLE MOBILE ELEMENTS WITH ENHANCED GENOMIC SITE SELECTION | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1655 | 2 |
| 1634 | 2 |
| 1636 | 2 |
| 1626 | 2 |
| 1642 | 2 |
| 1647 | 2 |
| 1633 | 2 |
| 1674 | 1 |
| 1661 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19558906 | METHODS AND COMPOSITIONS FOR REDUCING MUSCLE LOSS AND/OR INHIBITING SARCOPENIA ASSOCIATED WITH WEIGHT LOSS | Myos Corp. | BOECKELMAN, JACOB A | 1655 | §103§112DP | Final Rejection | — | Pending | Mar 06, 2026 |
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | Morphosys GmbH | PAK, MICHAEL D | 1674 | §112DP | Final Rejection | — | Pending | Oct 20, 2025 |
| 19065181 | STEM CELL-SPECIFIC PROMOTER FROM SACCHARUM AND METHODS FOR INCREASING FATTY ACID AND/OR OIL ACCUMULATION | The Board Of Trustees Of The University Of Illinois | HWU, JUNE | 1661 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18961853 | Single Cell Encapsulation in Compartmentalized Hydrogel Coatings | The Board Of Trustees Of The University Of Illinois | THUESON, HANNA MARIE | 1638 | §102§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18848589 | Adenoviral Mediated Targeting of Activated Immune Cells | Vector Biopharma AG | TINSLEY, BRENDAN THOMAS | 1634 | §112 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18805952 | BROCCOLI EXTRACT, NUTRACEUTICAL, AND METHODS OF TREATING INFLAMMATION AND CANCER | The Board Of Trustees Of The University Of Illinois | FIEBIG, RUSSELL G | 1655 | §101§103§112 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18723927 | NONHUMAN STEM CELLS AND THEIR USE FOR PRODUCTION OF CULTURED MEAT | Atelier Meats Corp. | MOLOYE, TITILAYO | 1632 | §103§112 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18706257 | TRANSPOSABLE MOBILE ELEMENTS WITH ENHANCED GENOMIC SITE SELECTION | UNIVERSITY OF HAWAII | VANHORN, ABIGAIL LOUISE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | Athebio AG | COFFA, SERGIO | 1658 | §102§103§112 | Non-Final OA | 86d overdue | Pending | Apr 11, 2024 |
| 18599832 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | The Trustees of Dartmouth College | COUGHLIN, MATTHEW P | 1626 | §103§112DP | Final Rejection | — | Pending | Mar 08, 2024 |
| 18442492 | Variants of Ankyrin Repeat Domains | Athebio AG | TSUI, YUNG-SHENG M | 1684 | §112DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18427042 | METHOD OF USING PACAP AND VIP PEPTIDES FOR DETECTING SHED OR CIRCULATING TUMOR CELLS IN BIOLOGICAL FLUIDS | Thomas Jefferson University | LU, CHENG | 1642 | §101§112DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18567159 | PHOTOACTIVATABLE GASDERMIN PROTEINS | The Board Of Trustees Of The University Of Illinois | STOICA, ELLY GERALD | 1647 | §102§112 | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18513938 | BIOINSECTICIDAL COMPOSITIONS CONTAINING MONOTERPENES AND METHODS OF USE THEREOF | UNIVERSITY OF HAWAII | TCHERKASSKAYA, OLGA V | 1615 | §102§103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18275463 | VACCINE AND METHODS FOR PREVENTING FILARIASIS AND DIROFILARIASIS | Pai Life Sciences Inc. | GANGLE, BRIAN J | 1645 | §112 | Final Rejection | 48d | Pending | Aug 02, 2023 |
| 18268032 | BURKHOLDERIA VACCINES AND THERAPEUTICS | UNIVERSITY OF HAWAII | MORGAN, BAILEY MICHELLE | 1645 | §101§102 | Final Rejection | 14d | Pending | Jun 16, 2023 |
| 18307253 | TOPICAL FORMULATIONS | Proveda Corporation | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 139d overdue | Pending | Apr 26, 2023 |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | Morphosys GmbH | LU, CHENG | 1642 | §112 | Non-Final OA | — | Pending | Mar 21, 2023 |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | St. Jude Children's Research Hospital | LANDSMAN, ROBERT S | 1647 | §103 | Final Rejection | 24d overdue | Pending | Mar 14, 2023 |
| 18178736 | METHODS AND MICROFLUIDIC DEVICE FOR PRODUCING EXTRACELLULAR VESICLES | The Board Of Trustees Of The University Of Illinois | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Non-Final OA | 23d | Pending | Mar 06, 2023 |
| 18043095 | ALGINATE-COATED MESENCHYMAL STROMAL AND PROGENITOR CELLS AND METHODS FOR USING THE SAME | The Board Of Trustees Of The University Of Illinois | CONNORS, ALEXANDRA F | 1634 | §103 | Final Rejection | — | Pending | Feb 27, 2023 |
| 18042015 | COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA | St. Jude Children's Research Hospital | WHITEMAN, BRIAN A | 1636 | §103 | Final Rejection | 2d overdue | Pending | Feb 17, 2023 |
| 17919622 | SYSTEM AND METHOD FOR MICRODIALYSIS FOR IN-VITRO RELEASE TESTING OF DOSAGE FORMS | Ortiv-Q3 Research Pvt. Ltd. | HERBERT, MADISON TAYLOR | 1758 | §103§112 | Non-Final OA | 34d | Pending | Oct 18, 2022 |
| 17913535 | Hypoimmunogenic Cells and Methods and Compositions for Their Production | Rxcell Inc. | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
| 17833231 | METHOD FOR DESIGNING A PROBE COMBINATION | Eiken Kagaku Kabushiki Kaisha | KAPUSHOC, STEPHEN THOMAS | 1683 | Other | Final Rejection | — | Pending | Jun 06, 2022 |
| 17750968 | VACCINE AND METHODS FOR DETECTING AND PREVENTING FILARIASIS | The Board Of Trustees Of The University Of Illinois | ZEMAN, ROBERT A | 1645 | §112Other | Non-Final OA | — | Pending | May 23, 2022 |
| 17433900 | ORALLY INGESTED COMPOSITION FOR IMPROVING SLEEP | Wellnas.Co., Ltd. | CHICKS, ASHLI ARIANA | 1626 | §103DP | Final Rejection | — | Pending | Aug 25, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial68.0% of resolved applications prosecuted by Licata & Tyrrell P.C. were allowed, across 2,256 applications in USPTO records.
4.30 office actions per allowed application on average.
27 pending office actions as of October 2026, for 16 clients, before 26 examiners in 18 art units.
